Strategic Acquisition Following PerkinElmer's acquisition of Covaris in December 2023, there is increased potential for cross-selling advanced sample preparation tools within PerkinElmer’s extensive customer network across genomics, proteomics, and drug discovery sectors.

Innovative Technologies Covaris's proprietary AFA technology offers unique non-contact, isothermal ultrasonic processes that can be leveraged to develop new, more efficient products or enhance existing workflows in genomics and proteomics labs.

Expanding Automation The recent launch of automatable workflows for FFPE sample processing indicates a market opportunity to promote automation solutions that improve throughput and reproducibility for laboratories handling large-scale molecular analysis.

Emerging Market Needs With extensive applications in drug discovery, including novel formulations and compound management, Covaris presents opportunities to partner with pharma and biotech firms seeking cutting-edge sample prep tools to accelerate research pipelines.

Security and Data Management The recent data breach highlights a need for enhanced cybersecurity measures, which could open doors for security solution providers to engage with Covaris and its customers on protecting sensitive research data and intellectual property.